VERAXA Biotech AG (NASDAQ: VRXA) announced it has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (PEI) regarding the underlying biology and proposed non-clinical development plan for its lead proprietary BiTAC-TCE cancer therapy program. The regulatory feedback provides greater clarity on the company’s proposed development strategy and indicates that the agency understands the biological rationale behind its dual-targeting, conditionally active BiTAC-TCE platform, representing an early step in advancing the program toward clinical development.
The BiTAC-TCE platform is designed to selectively target cancer cells that express two specific antigens, while sparing cells that express only one antigen. This dual-targeting mechanism aims to improve the therapeutic index—the balance between efficacy and safety—compared to traditional T-cell engagers that target a single antigen. According to VERAXA, preclinical data presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 demonstrated that its lead BiTAC-TCE candidate selectively targeted cancer cells expressing both intended targets, while cells expressing only one target were spared. The studies also showed a favorable safety profile with efficacy comparable to a traditional T-cell engager, supporting the potential for an improved therapeutic index.
For business and technology leaders, this development underscores the growing importance of precision medicine in oncology. The BiTAC-TCE platform represents a next-generation approach to immunotherapy, aiming to reduce off-target toxicities that often limit the use of T-cell engagers. If successful, this could lead to more effective cancer treatments with fewer side effects, potentially expanding the patient population eligible for such therapies. The regulatory feedback from PEI is a critical milestone, as it validates the scientific rationale behind the platform and provides a clearer pathway to clinical trials.
VERAXA Biotech AG, founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. The company’s pipeline includes proprietary BiTAC formats and ADCs guided by rigorous quality-by-design principles.
Investors and industry observers will be watching for further updates on the BiTAC-TCE program, as positive clinical data could position VERAXA as a key player in the competitive immuno-oncology landscape. The company’s ability to navigate regulatory requirements and demonstrate clinical benefit will be crucial for future success.
For more information, visit the company’s newsroom at http://ibn.fm/VRXA.
